Search results for "Immunocompromised"

showing 10 items of 98 documents

Prophylaxis and treatment of hepatitis B in immunocompromised patients.

2007

The literature on hepatitis B virus (HBV) in immunocompromised patients is heterogeneous and referred mainly to the pre-antivirals era. Today a rational approach to the problem of hepatitis B in these patients provides for: (a) the evaluation of HBV markers and of liver condition in all subjects starting immunosuppressive therapies (baseline), (b) the treatment with antivirals (therapy) of active carriers, (c) the pre-emptive use of antivirals (prophylaxis) in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk, (d) the biochemical and hepatitis B surface antigen (HBsAg) monitoring (or universal prophylaxis, in case of high risk immunos…

HBsAgmedicine.medical_specialtyHepatitis C virusmedicine.medical_treatmentLiver transplantationTransplantmedicine.disease_causeGastroenterologyAntiviral AgentsImmunocompromised HostAnimals; Antiviral Agents; Carrier State; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Humans; Immunocompromised Host; Liver Transplantation; Tissue Donors; TransplantationAntivirals; HBV; Immunosuppression; Transplants;Internal medicineHBVMedicineAnimalsHumansAntiviralHepatitis B virusTransplantationHepatitis B Surface AntigensHepatologybusiness.industryGastroenterologyvirus diseasesHepatitis Bmedicine.diseaseHepatitis BHepatitis B Core Antigensdigestive system diseasesTissue DonorsLiver TransplantationTransplantationHBeAgImmunologyCarrier StateHepatitis D virusbusinessImmunosuppression
researchProduct

Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: Real-life experience from the French CAREPI study group

2021

Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemiplimab. Endpoints were best overall response rate (BOR), progression-free survival (PFS), overall survival (OS), duration of response (DOR) and safety. The 245 patients (mean age 77 years, 73% male, 49% prior systemic treatment, 24% immunocompromised, 27% Eastern Cooperative Oncology Group performance status (PS) ≥ 2) had laCSCCs (35%) or mCSCCs (65%). For the 240 recipients of ≥1 infusion(s), the BOR was 50.4% (complete, 21%

Cancer Researchmedicine.medical_specialtycutaneous squamous cell carcinomaLocally advancedBest Overall Response[SDV.CAN]Life Sciences [q-bio]/CancerGastroenterologyArticle030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicineOverall survivalMedicineAdverse effectGroup performanceRC254-282Immune statusbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensMean agemedicine.diseasechronic dermatosisToxic epidermal necrolysis3. Good healthimmunocompromisedreal-life settingOncology030220 oncology & carcinogenesisPD-1–blocking antibodycemiplimabbusiness[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
researchProduct

Survival in Immunocompromised Patients Ultimately Requiring Invasive Mechanical Ventilation: A Pooled Individual Patient Data Analysis

2021

Rationale: Acute respiratory failure (ARF) is associated with high mortality in immunocompromised patients, particularly when invasive mechanical ventilation is needed. Therefore, noninvasive oxygenation/ventilation strategies have been developed to avoid intubation, with uncertain impact on mortality, especially when intubation is delayed. Objectives: We sought to report trends of survival over time in immunocompromised patients receiving invasive mechanical ventilation. The impact of delayed intubation after failure of noninvasive strategies was also assessed. Methods: Systematic review and meta-analysis using individual data (IPD) of studies which focused on immunocompromised adult patie…

Pulmonary and Respiratory MedicineMechanical ventilationmechanical ventilation.medicine.medical_specialtybusiness.industrymedicine.medical_treatmentHigh mortalityPatient dataAcute respiratory failureCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicine030228 respiratory systemMedicineAcute respiratory failure030212 general & internal medicinebusinessIntensive care medicineImmunocompromisedAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Host immune response to Cryptosporidium parvum infection

2010

Species of the genus Cryptosporidium are protozoan parasites (Apicomplexa) that cause gastroenteritis in animals and humans. Of these Cryptosporidium parvum and Cryptosporidium hominis are the major causative agents of human cryptosporidiosis. Whereas infection is self-limiting in the immunocompetent hosts, immunocompromised individuals develop a chronic, life-threatening disease. As specific therapeutic or preventive interventions are not yet available, better understanding of the immune response to the parasite is required. This minireview briefly summarizes the factors involved in the innate and acquired immune response in this pathogen-host interaction with an emphasis on more recent da…

T-Lymphocytesanimal diseasesAIDS-Related Opportunistic InfectionsImmunologyAntibodies ProtozoanCryptosporidiosisAdaptive ImmunityBiologyNitric OxideImmunocompromised HostMiceImmune systemIntestinal mucosaImmunityparasitic diseasesAnimalsHumansIntestinal MucosaCryptosporidium parvumB-LymphocytesPhagocytesAIDS-Related Opportunistic InfectionsComplement System ProteinsDendritic CellsGeneral MedicineAcquired immune systembiology.organism_classificationVirologyImmunity InnateKiller Cells NaturalDisease Models AnimalInfectious DiseasesCryptosporidium parvumImmunologyCytokinesParasitologyImmunocompetenceImmunocompetenceCryptosporidium hominisExperimental Parasitology
researchProduct

Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients

2020

Abstract Diagnosis, treatment, and management of invasive mould infections (IMI) are challenged by several risk factors, including local epidemiological characteristics, the emergence of fungal resistance and the innate resistance of emerging pathogens, the use of new immunosuppressants, as well as off-target effects of new oncological drugs. The presence of specific host genetic variants and the patient's immune system status may also influence the establishment of an IMI and the outcome of its therapy. Immunological components can thus be expected to play a pivotal role not only in the risk assessment and diagnosis, but also in the treatment of IMI. Cytokines could improve the reliability…

AdultMalemedicine.medical_specialtyTreatment responseAntifungal Agentshemato-oncological malignanciesAspergillosismucormycosis03 medical and health sciencesImmunocompromised HostImmune systemSDG 3 - Good Health and Well-beingInternal medicineNeoplasmsEpidemiologyimmunological statusmedicineHumansIntensive care medicine030304 developmental biologyAgedAged 80 and over0303 health sciencesHematology030306 microbiologybusiness.industryinvasive pulmonary aspergillosishematologyMucormycosisCancerReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseaseInfectious Diseaseshemato-oncological malignancies; hematology; immunological status; invasive pulmonary aspergillosis; mucormycosisAcademicSubjects/SCI00960FemaleOriginal ArticleRisk assessmentbusinessAcademicSubjects/MED00010Invasive Fungal Infections
researchProduct

A unique fatal case of Waterhouse–Friderichsen syndrome caused by Proteus mirabilis in an immunocompetent subject

2019

Abstract Introduction: The Waterhouse–Friderichsen syndrome (WFS), also known as purpura fulminans, is a potentially lethal condition described as acute hemorrhagic necrosis of the adrenal glands. It is often caused by infection. Classically, Neisseriae meningitidis represents the main microorganism related to WFS, although, infrequently, also other infectious agents are reported as a possible etiologic agent. The authors report the first case of death due to Proteus mirabilis infection, with postmortem evidence of WFS. Patient concerns: After a facial trauma that provoked a wound on the nose, the subject, a healthy 40-years old man, was conducted to the local hospital (in Sicily, Italy) af…

AdultMalemedicine.medical_specialtySepsiforensic sciencesAutopsyGastroenterologysepsisSepsisImmunocompromised Host03 medical and health sciences0302 clinical medicineSettore MED/43 - Medicina LegaleInternal medicinemedicineWaterhouse–Friderichsen syndromeHumansClinical Case Report030212 general & internal medicineLeukocytosisProteus mirabilisWaterhouse-Friderichsen syndromeDisseminated intravascular coagulationbiology4900business.industryBilateral massive adrenal hemorrhageWaterhouse-Friderichsen syndrome: XGeneral Medicinemedicine.diseasebiology.organism_classificationProteus InfectionProteus mirabilisBilateral massive adrenal hemorrhage; Forensic sciences; Proteus mirabilis infection; Sepsis; Waterhouse-Friderichsen syndrome; Adult; Humans; Male; Proteus Infections; Waterhouse-Friderichsen Syndrome; Immunocompromised Host; Proteus mirabilisProteus mirabilis infection030220 oncology & carcinogenesisForensic sciencemedicine.symptomProteus InfectionsbusinessAdrenal HemorrhageResearch ArticleHumanPurpura fulminansMedicine
researchProduct

Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries

2005

Background. Amphotericin B is a widely used broad-spectrum antifungal agent, despite being associated with significant adverse events, including nephrotoxicity. Methods. The present prospective study collected data on outcomes for 418 adult patients treated consecutively with polyenes in hematology and oncology wards in 20 hospitals in Europe. Results. Patients initially received amphotericin B deoxycholate (62% of patients), liposomal amphotericin B (27%), or other lipid formulations of amphotericin B (11%). Of the patients initially treated with amphotericin B deoxycholate, 36% had therapy switched to lipid formulations of amphotericin B, primarily because of increased serum creatinine le…

AdultMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsRenal functionPolyenesGastroenterologyNephrotoxicityImmunocompromised HostAmphotericin BAmphotericin B deoxycholateInternal medicineAmphotericin BmedicineHumansProspective StudiesAdverse effectProspective cohort studyAgedHematologybusiness.industryMortality rateLength of StayMiddle AgedSurgeryEuropeInfectious DiseasesMycosesFemaleKidney Diseasesbusinessmedicine.drug
researchProduct

Molecular Diagnosis of Toxoplasmosis in Immunocompromised Patients: a 3-Year Multicenter Retrospective Study

2015

ABSTRACT Toxoplasmosis is a life-threatening infection in immunocompromised patients (ICPs). The definitive diagnosis relies on parasite DNA detection, but little is known about the incidence and burden of disease in HIV-negative patients. A 3-year retrospective study was conducted in 15 reference laboratories from the network of the French National Reference Center for Toxoplasmosis, in order to record the frequency of Toxoplasma gondii DNA detection in ICPs and to review the molecular methods used for diagnosis and the prevention measures implemented in transplant patients. During the study period, of 31,640 PCRs performed on samples from ICPs, 610 were positive (323 patients). Blood ( n …

Microbiology (medical)Microbiological Techniquesmedicine.medical_specialtyMESH: Molecular Diagnostic TechniquesAsymptomaticPolymerase Chain Reactionlaw.inventionImmunocompromised Host[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseaseslawInternal medicinemedicineMESH: Immunocompromised HostPrevalenceHumansComputingMilieux_MISCELLANEOUSPolymerase chain reactionImmunodeficiencySurvival analysisMESH: PrevalenceRetrospective Studies[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/HealthMESH: Humansbusiness.industryIncidence (epidemiology)MESH: ToxoplasmaMESH: Microbiological TechniquesRetrospective cohort studyMESH: Polymerase Chain ReactionMESH: Retrospective Studiesmedicine.diseaseSurvival AnalysisToxoplasmosis3. Good healthSurgeryMESH: France[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyMolecular Diagnostic TechniquesMESH: Survival AnalysisChemoprophylaxisMESH: ToxoplasmosisParasitologyFrancemedicine.symptombusinessToxoplasmaToxoplasmosis
researchProduct

Synergism between the components of the bipartite major immediate-early transcriptional enhancer of murine cytomegalovirus does not accelerate virus …

2009

Major immediate-early (MIE) transcriptional enhancers of cytomegaloviruses are key regulators that are regarded as determinants of virus replicative fitness and pathogenicity. The MIE locus of murine cytomegalovirus (mCMV) shows bidirectional gene-pair architecture, with a bipartite enhancer flanked by divergent core promoters. Here, we have constructed recombinant viruses mCMV-ΔEnh1 and mCMV-ΔEnh2 to study the impact of either enhancer component on bidirectional MIE gene transcription and on virus replication in cell culture and various host tissues that are relevant to CMV disease. The data revealed that the two unipartite enhancers can operate independently, but synergize in enhancing MI…

DNA ReplicationGene Expression Regulation ViralTranscription GeneticvirusesEnhancer RNAsBiologyVirus ReplicationVirusImmediate-Early ProteinsImmunocompromised HostMiceTranscription (biology)VirologyGene expressionAnimalsEnhancerAntigens ViralCells CulturedGeneticsPromoterFibroblastsVirologyEnhancer Elements GeneticViral replicationCell cultureDNA ViralJournal of General Virology
researchProduct

Identification of fatal outcome in a childhood nasopharyngeal carcinoma patient by protein expression profiling.

2017

Nasopharyngeal carcinoma (NPC) is a rare disease in children with good prognosis and high cure rate. Nevertheless, certain patients have an unfavorable prognosis due to development of refractory NPC that is unresponsive to any therapeutic strategies. The current study studies a case of a 17 years-old female with non-keratinizing NPC type IIb (T2N0M0), who passed away as a consequence of resistance to chemo-, radio- and β-interferon therapy, and to an allogenic stem cell transplantation. In order to identify factors that lead to treatment failure and fatal outcome, immunohistochemical analyses of different tumor biomarkers and hierarchical cluster analysis were performed and compared with th…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtyHerpesvirus 4 HumanAdolescentBiologymedicine.disease_causeVirusViral Matrix Proteins03 medical and health sciencesImmunocompromised Host0302 clinical medicineLymphocytes Tumor-InfiltratingInternal medicineotorhinolaryngologic diseasesmedicineBiomarkers TumorHumansProspective StudiesChildImmunodeficiencyNasopharyngeal CarcinomaTumor-infiltrating lymphocytesGene Expression ProfilingVaricella zoster virusCancermedicine.diseasePrognosisImmunohistochemistryTransplantationstomatognathic diseases030104 developmental biologyHerpes simplex virusOncologyNasopharyngeal carcinomaDrug Resistance Neoplasm030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalStem Cell TransplantationInternational journal of oncology
researchProduct